Structural and Evolutionary Relationships among
Protein Tyrosine Phosphatase Domains
Jannik N.
Andersen,1,2,*
Ole H.
Mortensen,3
Günther H.
Peters,1,
Paul G.
Drake,1
Lars F.
Iversen,4
Ole H.
Olsen,5
Peter G.
Jansen,6
Henrik S.
Andersen,5
Nicholas K.
Tonks,2 and
Niels Peter H.
Møller1,*
 |
TEXT |
With the current access to
the whole genomes of various organisms and the completion of the first
draft of the human genome, there is a strong need for a
structure-function classification of protein families as an initial
step in moving from DNA databases to a comprehensive understanding of
human biology. As a result of the explosion in nucleic acid sequence
information and the concurrent development of methods for
high-throughput functional characterization of gene products, the
genomic revolution also promises to provide a new paradigm for drug
discovery, enabling the identification of molecular drug targets in a
significant number of human diseases. This molecular view of diseases
has contributed to the importance of combining primary sequence data with three-dimensional structure and has increased the awareness of
computational homology modeling and its potential to elucidate protein
function. In particular, when important proteins or novel therapeutic
targets are identified
like the family of protein tyrosine
phosphatases (PTPs) (reviewed in reference 53)
a
structure-function classification of such protein families becomes an
invaluable framework for further advances in biomedical science. Here,
we present a comparative analysis of the structural relationships among
vertebrate PTP domains and provide a comprehensive resource for
sequence analysis of phosphotyrosine-specific PTPs.
PTPs are a key group of signal transduction enzymes which, together
with protein tyrosine kinases, control the levels of cellular protein
tyrosine phosphorylation. Protein tyrosine kinases phosphorylate cellular substrates on tyrosine residues, and much progress has been
made over the last 20 years in elucidating their significance in signal
transduction (for reviews, see references 26, 30, 31, 33, 71, and
72). However, it is only recently that the complexities of the
PTPs have been appreciated. Thus, today it is recognized that the
capacity of PTPs to dephosphorylate phosphotyrosine residues
selectively on their substrates plays a pivotal role in initiating,
sustaining and terminating cellular signaling (for reviews, see
references 1, 4, 19, 32, 35, 46, 55, and 83). It has been
shown that both the catalytic domain and noncatalytic segments of the
PTPs contribute to the definition of substrate specificity in vivo.
Whereas noncatalytic domains may target the PTPs to specific
intracellular compartments in which the effective local concentration
of substrate is high (3, 19, 51), the PTP catalytic
domains themselves confer site-selective protein dephosphorylation by
recognizing both the phosphotyrosine residue to be dephosphorylated and
its flanking amino acids in the substrate. The combination of
structural studies, kinetic analysis of PTP domains (37, 74, 76,
90, 91, 96), and studies involving substrate-trapping mutants
(20, 23, 89) as well as PTP chimeras (60, 82)
has convincingly demonstrated that isolated PTP domains may exhibit
exquisite substrate selectivity.
The structurally conserved PTP domain defines membership of the PTP
family, and three groups of enzymes are capable of dephosphorylating tyrosine-phosphorylated residues (57): (i) classical PTPs,
(ii) dual-specificity PTPs, and (iii) low-molecular-weight PTPs. The dual-specificity PTPs and low-molecular-weight PTPs will not be considered further but have been reviewed (43, 70). The
classical PTPs, which are the focus of the present study, encompass
both transmembrane receptor-like and nontransmembrane enzymes, and the
wide spectrum of protein domains present within this family highlight
their diverse cellular functions. Most transmembrane receptor-like PTPs
(RPTPs) contain two cytoplasmic PTP domains, a membrane proximal domain
(D1) and a membrane distal domain (D2), and in addition have a single
transmembrane segment and an extracellular domain.
As the study of PTPs has developed, the availability of an impressive
number of X-ray crystal structures (for an updated list, see reference
53) and phylogenetically divergent cDNAs has permitted a
detailed structural analysis of the evolutionary relationships among
vertebrate PTP domains. Together with numerous enzymological studies
revealing insights into the mechanism of PTP catalysis (12, 14,
25, 34, 47, 68, 77, 80, 97-99, 101), this development has
permitted us to combine an extensive set of amino acid sequences with
representative three-dimensional protein structures to derive new and
refined information regarding PTP structure, substrate recognition, and
evolutionary conservation. Because perturbed levels of tyrosine
phosphorylation are associated with diseases such as cancer,
autoimmunity, and allergy, we hope that this comprehensive analysis of
the PTP family may assist in providing the structural basis for novel
therapeutic strategies involving the development of selective PTP inhibitors.
In the present study, we have compiled a total of 319 vertebrate PTP
sequences, including splice variants and partially overlapping sequences. Subsequent analysis narrowed these 319 GenBank entries down
to 113 distinct PTP catalytic domain sequences (including non-transmembrane PTPs and domains D1 of RPTPs) and 38 domain D2
sequences from human and other vertebrate species. From this collection
of 151 PTP domain sequences, we identified 37 distinct human PTP genes,
which we aligned to assist in the identification of conserved regions.
This sequence comparison allowed the classification of the vertebrate
PTP family into 17 principal subtypes. The motifs identified from our
amino acid sequence alignment are reviewed in terms of their location
in the tertiary structure and, where relevant, their catalytic
function. As a low-resolution and automated homology modeling approach,
we applied the methodology of C
-regiovariation score analysis
(10, 11) to identify foci within the PTP domain tertiary
structure, where amino acid conservation extended in three dimensions.
The conserved foci identified by this approach are discussed including
a previously unrecognized conserved cluster of residues located on the
face of the molecule opposite the active site.
Collection of unique vertebrate PTP domains.
Following the
identification of the first PTP in 1988 (84), intense
efforts in the application of PCR and low-stringency screening led to
the rapid discovery of a wide variety of other PTP family members. As
often happens in rapidly developing research fields, several identical
PTPs were independently cloned by different research groups and hence
given different names and accession numbers. Consequently, the first
step in our structural study was to compile a database of unique PTP
domains. A BLAST search (2) of the National Center for
Biotechnology Information (NCBI) GenBank database was performed using
nucleotide sequences encoding several divergent PTP catalytic domains
(PTP1B, SHP1, MEG2, PEST, PTPH1, PTPD1, CD45, RPTPµ, LAR,
RPTP
, RPTP
, RPTP
, STEP, and the PTP-like protein IA2). This
sequence similarity search generated over 3,500 database hits that,
following the exclusion of expressed sequence tags and sequences
encoding dual specificity and low-molecular-weight phosphatases,
identified 319 vertebrate PTP entries. Alignment of the 5' untranslated
regions and the amino acid sequences of these 319 entries revealed a
large number of different splice variants, partially overlapping
sequences, and duplicate database entries. In total, 113 distinct PTP
catalytic domains and 38 domain D2 sequences from tandem domain RPTPs
were uncovered. This collection of PTP domains contains 37 human PTP
genes and ortholog sequences from vertebrate species (Table
1). Our compilation of
PTP-related sequences illustrates the
redundancies often observed among GenBank database entries. Moreover,
since many of the deposited sequences lack structural or functional
annotation, there is a strong requirement for grouping these entries in
order to gain access to the combined body of biochemical, structural,
and/or functional information known for any given PTP. To this end, we
have grouped the entries in Table 1 based on PTP domain sequence
similarity (by subtype) and have identified the most likely human
orthologs. In addition, to facilitate access to MEDLINE literature for
any given PTP of interest, an electronic version of Table 1 can be
retrieved (http://science.novonordisk.com/ptp), in which the
accession numbers are hyperlinked to the NCBI website and PubMed
literature database (http://www.ncbi.nlm.nih.gov). We have also
mapped the chromosomal locations of the 37 human PTPs described in this
study, allowing a detailed description of their intron and exon
structure. Genomic clones, EMBL accession numbers, and the position of
these PTPs in the human genome are summarized in Table
2. In addition, we acknowledge that the
draft of the human genome contains additional sequences that conform to
the PTP consensus motifs, but the expression of these hypothetical proteins has not yet been verified. Only transcripts that have been
confirmed from in vitro or in vivo studies are considered in the
present structure-function analysis of PTP domains.
Primary sequence alignment of PTP domains.
To provide a
platform for classification of members of the PTP family and for the
identification of conserved residues, a multiple-sequence alignment was
constructed using the entire set of vertebrate PTPs identified above
(Table 1). In Fig. 1, we have reduced the
alignment to a sequence comparison between the 37 human
PTP domains, but the extended version used in our
analysis can be retrieved from the World Wide Web
(http: //science.novonordisk.com/ptp) and includes all 113 vertebrate PTP catalytic domains. To enable the assessment of both the
level of conservation and the degree of sequence variation, the
alignment is color coded according to amino acid identity (see legend
to Fig. 1). The N- and C-terminal boundaries for this alignment
correspond to residues 1 to 279 in PTP1B and encompass all invariant
residues and structurally conserved elements. In the past, the PTP
domain has been described to consist of ~250 amino acids, but the
extensive set of PTPs included in this multiple-sequence alignment,
combined with structural knowledge and secondary-structure prediction
algorithms, has permitted us to identify conservation at the N terminus
of the PTP domain comprising the
1' and
2' helices of PTP1B
(37) (Fig. 1). We now define the PTP domain as comprising
~280 residues. In Fig. 1, an alignment of domain D2 of RPTPs is
included, but these domains were not used in the definition of the PTP
consensus sequence.



View larger version (318K):
[in this window]
[in a new window]
|
FIG. 1.
Sequence comparison of human PTP domains. Shown is an
amino acid sequence alignment of 37 human PTP domains (from
nontransmembrane PTP and RPTP domains D1) (above) and comparison with
domain D2 sequences of RPTPs (below). Amino acids are numbered
according to the residue position in human PTP1B. The locations of
-helices and -strands (based on the X-ray crystal structure of
PTP1B [7]) are shown at the top of the alignment.
Twenty-two invariant residues (underscored) and 42 highly conserved
residues (>80% identity) are indicated at the bottom of the
alignment. The PTP consensus motifs (M1 to M10) are detailed in Table
2. Amino acids are color coded according to their degree of
conservation, as indicated below the alignment. Nonconserved residues
involved in the definition of substrate selectivity-determining regions
are boxed with black lines (see text and Fig. 9). The four-residue
conserved linker in tandem RPTP enzymes is boxed in yellow (above) and
corresponds to encircled area 1 in Fig. 8. Sequences were aligned using
the Clustalw algorithm and the Genetics Computer Group PileUp software
(version 8.1) by applying the BLOSUM 62 scoring matrix together with
default gap creation and extension penalty. Alignment of the N termini
of the PTP domains was guided by crystallographic structural data and
secondary structure predictions (nnpredict at
http://www.cmpharm.ucsf.edu). The complete alignment of all vertebrate
PTP domains can be retrieved (http://science.novonordisk.com/ptp)
in several standard GCG formats, including MSF, TFA, and ALN.
|
|
PTP family can be classified into 17 subtypes.
Since
phylogenetic analysis of sequence alignments serves as a useful tool
for the classification of homologous proteins, we derived a
phylogenetic tree from our alignment of 113 PTP catalytic domains (Fig.
2). The clustering of sequences into
divergent branches of this tree provided a basis for subdivision of PTP
family members (see figure legend for details). In total, 17 principal
PTP subtypes were identified as indicated in Fig. 2. In addition, all
PTP domain D1 sequences from tandem domain RPTPs clustered into one
major trunk of the phylogenetic tree, allowing the definition of a PTP supertype encompassing these five RPTP subtypes (R1/R6, R2A, R2B, R4,
and R5). The high intrasubtype sequence identity of 60 to 80% among
domain D1 of these RPTPs, compared to 45 to 60% among PTP domains of
the RPTP
-like subtype (R3), which contain only one PTP domain,
supports earlier suggestions that during evolution, intragenic
catalytic domain duplication (i.e., duplication of the PTP domain
within an ancestral PTP gene) preceded gene duplication (88). Consistent with this concept, all domain D2
sequences also clustered into one separate branch of the phylogenetic
tree (data available at http://science.novonordisk.com/ptp),
suggesting structural, and perhaps functional, conservation among these
PTP domains. The result of the present classification system, together with a diagram of the overall domain structure of a representative member of each PTP subtype, is presented in Fig.
3.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 2.
Classification of family of PTPs into 17 subtypes. Shown
is an unrooted tree derived from the alignment of 113 vertebrate PTP
domain sequences (residue positions 1 to 279 in human PTP1B). The tree
was drawn by the neighbor-joining method (73). The
horizontal distance indicates the degree of sequence divergence, and
the scale at the top corner represents the number of substitution
events (10 per 100 amino acids). Seventeen PTP domain subtypes were
identified from the phylogram: nine nontransmembrane subtypes (NT1 to
NT9), five tandem receptor-like subtypes (R1/R6, R2A, R2B, R4, and R5),
and three single-domain RPTP subtypes (R3, R7, and R8 [subtype R8 is
believed to be catalytically inactive]). As a statistical test of the
significance of sequence similarity within PTP subtypes, bootstrap
values were calculated (values are at the dendogram node). With the
exception of the RPTP -like subtype (R3) and the tandem PTP domain
supertype, all subdivisions were assigned based on maximal bootstrap
values (1,000). (A tree including the PTP domain D2 sequences can be
viewed [http://science.novonordisk.com/ptp], and the raw data files
can also be retrieved in several standard GCG formats).
|
|

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 3.
Schematic representation of PTP family members.
Determination of sequence similarity among PTP catalytic domains (Fig.
2) was used to classify the PTP family of enzymes into nine
nontransmembrane PTP subtypes (NT) and eight RPTP subtypes (R). Only
the human PTPs are listed, and a representative member of each subtype
is shown. Synonyms and classifications of all vertebrate PTPs are given
in Table 1. PTPs having closely related catalytic domains also tend to
be similar in overall structural topology.
|
|
Sequence similarity between PTP domains can be used for overall
structural classification of PTP family.
A major finding from the
phylogenetic analysis of the alignment is the very close relationship
between PTP domain sequence similarity and the presence of similar
structural and functional domains in the full-length proteins (Fig. 3).
Thus, the RPTPs, previously classified by their extracellular domains
into nine distinct subtypes (8), are categorized into
virtually identical groups based solely on catalytic domain sequence
homology (hence the use of the existing nomenclature for the RPTPs)
(8). However, one difference lies with chicken PTP
.
Based on its unique extracellular segment, this PTP was previously
assigned to its own subtype (R6). but the present classification system
suggests that it is the avian homologue of CD45. Therefore, we have
included it within the CD45 subtype and defined it as R1/R6.
For the nontransmembrane PTPs, the nine subtypes defined from the
phylogenetic analysis of PTP domains also correlated with the presence
of particular regulatory and/or targeting domains. Thus, the SH2
domain-containing PTPs, SHP1 and SHP2, are classified as one PTP
subtype (NT2), and the three PTPs containing a carboxy-terminal PEST-like domain (viz. human BDP, PEST, and LyPTP) are categorized as
another distinct subtype (NT4) (Fig. 2). However, it should be noted
that the FERM domain-containing PTPs, which vary in their central
segments and contain distinct numbers of PDZ domains, fall into three
distinct subtypes (NT5, NT6, and NT7). Although HDPTP (85)
and PTPTyp (58) contain segments with a high content of
proline, glutamate, serine, and threonine residues (PEST-like domains),
they are categorized as distinct subtypes (NT8 and NT9). Since
PEST-like sequence annotation is subjective and these sequences do not
correspond to conserved protein domains in the Pfam and Interpro
databases (5), the functions of these PEST-like segments are most likely unrelated.
Another important observation from the phylogenetic mapping of PTP
domains relates to the traditional classification of this protein
family into two broad classes: transmembrane RPTPs and intracellular
nontransmembrane PTPs. Although we have maintained this conceptual
subdivision for the classifications shown in Fig. 2 and 3, it is
significant that several of the PTP subtypes (R3, R4, and R7) contain
both transmembrane and nontransmembrane enzymes. Thus, the PCPTP1-like
subtype (R7) contains both the receptor-like enzyme PCPTP1 (mouse
PTP-SL) and two cytoplasmic enzymes STEP and HePTP (mouse LCPTP), for
which no transmembrane isoforms have been identified so far. For the
RPTP subtype R3, alternative splicing of GLEPP1 mRNA (mouse PTP
)
generates either a cytoplasmic or transmembrane form of the enzyme
(67), and for PTP
(subtype R4), the alternate usage of
isoform specific 5' exons and promoters generates either a cytoplasmic
or transmembrane form of the enzyme (18). Since the above
examples illustrate that the classical subdivision of PTP family
members, based on the presence or absence of an extracellular and
transmembrane segment may be ambiguous, a novel classification system
based on catalytic domain sequence similarity, as described here, was
considered appropriate. We have made the phylogenetic tree
available (http://science.novonordisk.com/ptp), and we
hope it will serve as a useful tool for the classification of novel
PTPs discovered in the postgenomic area.
Ten conserved motifs define family of PTPs.
Another
application of the present PTP sequence alignment is the identification
of conserved motifs that define this class of signal-transducing
enzymes. In particular, the definition of consensus amino acid
sequences
either for the PTP family as a whole or for functional and
therapeutically interesting PTP subtypes
will help to probe genomes of
other organisms for the presence of PTP orthologs and thereby identify
relevant model organisms for rapid genetic analysis of the involvement
of PTPs in control of fundamental cellular functions.
In the present study, we have defined a conserved motif as a stretch of
three or more amino acids in which two of three of the residues are at
least 80% conserved by amino acid similarity (substitution groups are
specified in Table 3). Based on amino acid identity, 10 discrete and highly conserved motifs (M1 to M10) were
identified from the alignment of PTP domains (Table 3). In addition,
outside these motifs, seven single conserved residues were found
(Glu19, Glu115, Arg156, Arg169, Leu192, Arg254, and Arg257; residues
are numbered according to the numbering of human PTP1B) (Table
4). Several of the conserved residues
identified have previously been reviewed (6, 95), and
their functions have been studied extensively by site-directed
mutagenesis (20, 78) and X-ray crystallography (13,
95). However, the existing PTP consensus sequences in the
literature have been defined from a much smaller number of aligned
sequences, and some important structural (noncatalytic) motifs have
received less attention or, until now, have remained undisclosed (Table
3). Therefore, an overview of all motifs and their proposed function
together with an evaluation of their degree of conservation in
three-dimensional space is provided below.
View this table:
[in this window]
[in a new window]
|
TABLE 4.
Proposed roles of single conserved residues in vertebrate
PTP domains that reside outside the 10 PTP
motifsa
|
|
Superimposition of PTP domains reveals conserved C
-backbone
trace that allows evaluation of the multiple sequence alignment in 3D
space.
To date, X-ray crystallographic structures are available
for seven different PTP catalytic domains, including the
nontransmembrane enzymes (PTP1B, Yop51, SHP1, and SHP2) (7, 27,
79, 92) and RPTP domains (PTPµ, PTP
, and LAR) (29,
50, 56). When the crystal structures of vertebrate PTP domains
were superimposed, we observed a conserved fold and a consistent
C
-backbone trace (Fig. 4). This
striking conservation of tertiary structure allowed us to quantify the
degree of conservation of each amino acid residue in three dimensional
space (i.e., relative to the conservation of neighboring residues). In
brief, such low-resolution homology modeling, the so-called
C
-regiovariation score analysis (10, 11), uses the
information in a set of aligned sequences and calculates the average
degree of conservation which has occurred within a given "sphere of
influence" for each residue position along the folded polypeptide
backbone of a representative tertiary structure. The method has
previously identified interactive sites for cytochrome c,
the pancreatic trypsin inhibitor family of proteinases, and
carboxypeptidases A and B (10, 11). To avoid bias towards catalytic domains that are represented by a large number of ortholog sequences, we selected a nonredundant set of 37 aligned human PTP
catalytic domains (Fig. 1). In agreement with C
-regiovariation score
analyses of other protein families (10, 11), we observed that a 6- to 8-Å sphere of influence provides an optimal
signal-to-noise ratio and yields consistent results for different PTP
templates (not shown). All figures in the present work were produced
with a sphere of influence of 7 Å.

View larger version (86K):
[in this window]
[in a new window]
|
FIG. 4.
Crystal structures of vertebrate PTP domains show
conserved fold and consistent C -backbone trace. PTP1B (magenta),
RPTP (gray), RPTPµ (red), LAR (blue), SHP1 (green), and SHP2
(yellow) were aligned and superimposed using Quanta (Molecular
Simulations Inc.). For clarity, residues 280 to 298 (C terminal) of
PTP1B, 250 to 281 (N terminal) and 522 to 532 (C terminal) of SHP1, and
2 to 218 (N terminal) of SHP2 were omitted from the figure, as well as
D2 of LAR. The calculated RMS deviations between all C atoms between
PTP1B and other PTPs are as follows: PTP , 1.35 Å; RPTPµ,
2.72 Å; LAR D1, 2.78 Å; SHP1, 3.14 Å; and
SHP2, 2.74 Å. For comparison, the RMS deviation between
domains D1 and D2 of LAR is 1.3 Å. The X-ray structures are
compared in their native open conformation.
|
|
Structural motifs make up the most highly conserved regions in PTP
structure.
The score values for the C
-regiovariation analysis
are shown in Fig. 5. Conserved residues
in conserved surroundings are identified as peaks. Hydrophobic segments
in the primary amino acid sequence alignment make up the most highly
conserved microenvironments in the PTP structure. Thus, the structural
motifs TXXDFWXMXW (M5), IVMXT, (M6) and
KCXXYWP (M7) (Table 3) together form a densely packed
hydrophobic core with energetically favored T stacking (52) of their aromatic ring systems (Phe95, Trp96, Tyr124,
and Trp125). Extensive hydrophobic interactions were also observed between the stretch of amino acids DYINAS (M3) and
[F/Y]IAXQGP (M4), which packed together in the PTP
crystal structure by arrangement in parallel and anti-parallel
-sheets (Fig. 6). Hydrophobic packing is important for protein structures to gain stability
(16). In agreement with this concept, thermosensitive
variants of LAR, TC-PTP, and PTP1B (54, 86) were found to
contain mutations in the hydrophobic motifs above (M2 to M7),
indicating a critical role of these residues in stabilizing the
secondary structure of the PTP domain. Moreover, projection of the
secondary structure of PTP1B onto the alignment (Fig. 1) and
C
-regiovariation score values (Fig. 5) revealed that the
-sheets
and
-helixes in the structural motifs M2 to M6 are dominated by
conservative amino acid substitutions, whereas nonconservation
mutations frequently have been accepted in the regions flanking these
secondary structures. To visualize the conservation of the core of the
PTP structure, conserved residues are indicated on the C
-backbone
(Fig. 6).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 5.
The HCSAGXGR and IAXQGP motifs reside within the most
highly conserved microenvironment of the PTP structure. Residues
located within a highly conserved three dimensional space of the PTP
structure are identified by peaks. The C -regiovariation score was
calculated using the alignment information in Fig. 1 and the tertiary
structure of PTP1B as template. Neighboring residues were defined using
a three-dimensional 7-Å sphere of influence. Similar results were
obtained for a 5- to 8-Å sphere and when using PTP , PTPµ, or SHP2
as templates for C -regiovariation score analysis (results not
shown).
|
|

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 6.
Core structures within the PTP domain are highly
conserved and surface loops between secondary structure elements are
least conserved. Shown is a ribbon diagram indicating the positions of
conserved motifs (M1 to M10) within the tertiary structure. The degree
of conservation was determined from C -regiovariation score analysis
of 37 aligned human PTP catalytic domains (see Fig. 5). Areas of
conservation (blue, most conserved; red, least conserved) are
illustrated using the PTP1B catalytic domain as the representative
tertiary structure. Shown is the front view of PTP1B looking into the
active site. The catalytically essential Cys215 residue is shown in
yellow.
|
|
We found that the functional motif defined by the PTP signature
sequence,
VHCSXGXGR[T/S]
(M9),
together with the structural motif [F/Y]IAxQGP (M4),
constitutes the most highly conserved area within the PTP tertiary
structure (Fig. 5). Importantly, the C-terminal stretch of residues QGP
in motif M4 leads to the termination of a
-sheet and is involved in
a bend situated very near to the catalytic cysteine (Cys215) (Fig. 6).
Intriguingly, the conserved proline in the [F/Y]IAXQGP
motif (Pro87 in PTP1B) is replaced by a cysteine in SHP1 and SHP2,
which is likely to result in a more flexible main chain with a greater
configurational entropy (27, 92). Whereas the structural
motifs are detailed in Table 3, we will discuss further the role of
conserved residues in the four motifs (M1 and M8 to M10) that define
the catalytic functionality of PTP domains.
PTP signature motif or phosphate-binding loop (motif 9).
The
active site sequence
VHCSXGXGR[T/S]G
(residues 213 to 223 in PTP1B) defines the PTP family and is often
referred to as the PTP signature motif or the "PTP loop." Residues
in this motif (M9) form the phosphate-binding loop, which is located at
the base of the active site cleft. The cysteine in the PTP signature motif acts as a nucleophile and accepts phosphate transiently during
catalysis (25), and the invariant Arg221 is involved in
both substrate binding and in the stabilization of the phosphoenzyme intermediate (99). Our C
-regiovariation score analysis
identified two conserved polar residues (Glu115 and Arg257) in a
microenvironment of the PTP structure which otherwise has accommodated
many amino acid substitutions during evolution (Fig. 5). Importantly,
these two residues form hydrogen bonds with the PTP loop, with the
invariant Glu115 determining the position of Arg221 through a conserved salt bridge between the carboxy and guanidinium groups. Their invariance among human PTPs highlights their principal role in defining
the architecture and function of the phosphate-binding loop. The close
proximity of the catalytic Cys215 residue to main-chain amide groups of
the PTP loop and hydrogen bonding with both the side chain of Arg221
and the hydroxyl group of Ser222 stabilizes the thiolate (deprotonated)
form of the cysteine, favoring its function as a nucleophile (7,
94, 97). Moreover, theoretical investigations revealed that
Arg257 may also contribute to stabilizing the nucleophilic nature of
the active site cysteine (65). Mutation of the catalytic
Cys215 to serine or alanine abrogates all enzyme activity while
maintaining affinity for substrates in vitro, a feature that has been
successfully utilized to obtain structures of PTPs in complex with
phosphotyrosine peptide substrates (37, 74, 75, 91).
Phosphotyrosine recognition loop (motif 1).
Whereas the
phosphate group in the substrate phosphotyrosine residue is surrounded
by residues corresponding to the PTP signature motif (37,
99), aromatic (Tyr46 and Phe182) and nonpolar (Val49, Ala217,
and lle219) amino acids pack with the phenyl ring of the phosphotyrosine and delineate the boundaries of the active site binding
pocket (37). The fact that these five residues are
conserved by amino acid similarity suggests that the mechanism for
recognition of the phosphotyrosine moiety of the substrate is similar
among all tyrosine-specific PTPs. Collectively, the residues
KNRY (Lys43 to Tyr46) are known as the phosphotyrosine
recognition loop (37) since this element (M1) defines the
depth of the active site crevice and hence creates selectivity for
phosphotyrosine by excluding the hydrolysis of the shorter
phosphoserine or phosphothreonine residues in target proteins
(37, 91).
WPD loop (motif 8).
The binding of phosphopeptides to the PTP
loop promotes a major conformational change in the catalytic site
surface loop (residues 179 to 187) that moves several angstroms to
close the active site pocket and trap the bound phosphotyrosine
(37, 80). The amino acid sequence of this surface loop is
quite diverse, except for the WPDXGXP motif
that contains a general acid-base catalyst (Asp181) (98).
The presence of two proline residues (which do not support hydrogen
bonding) and a glycine in the hinge bend region of this segment is
critical for the dynamics of the WPD loop motion (63, 64).
Comparison of the structures of ligand-free form of the Yersinia PTP (Yop51) and the enzyme complexed with oxyanions
(77, 80) has revealed that an interaction between the
invariant tryptophan in the WPD loop (Trp354, equivalent to Trp179 in
PTP1B) and the above-mentioned arginine in the PTP loop (Arg409,
equivalent to Arg221 in PTP1B) plays an important role in closure of
the WPD loop. Enzyme kinetic analyses of this PTP has confirmed that
mutation of the hinge Trp179 disables catalysis (28, 42).
Closure of the WPD loop is critical for phosphoester hydrolysis, since
it positions Asp181 close to the scissile oxygen of the tyrosyl
substrate, allowing it to donate a proton to the phenolate leaving
group (reviewed in references 22 and 95). Consistent with
its role as a general acid catalyst, the substitution of Asp181 for an alanine allows phosphorylated substrates to form stable complexes with
the enzyme. This "substrate-trapping" mutation has been used to
enable isolation and identification of PTP substrates in vitro and in
vivo (20, 23, 89, 94). The Asp181-to-alanine mutation creates a more efficient substrate trap than the mutation in which the
active site Cys215 is changed to serine or alanine, possibly because
the former mutation promotes the hydrophobic properties of the active
site cleft and removes the potential for electrostatic repulsion
between the Asp181 and the phosphate moiety of the substrate (23,
94).
As can be seen from the alignment in Fig. 1, the WPD loop is strictly
conserved among PTP domains but not among domains D2 of RPTPs. Of the
RPTPs with a single PTP domain, only PTP-IA2 and PTP-IA2
have
accepted non conservative substitutions within the WPD motif, and the
substrate trapping alanine mutation (20) occurs naturally
in PTP-IA2. Since catalytic activity has not been shown for IA2 in
vitro, it has been suggested that its biological function is to compete
with catalytically active PTPs for specific substrates preventing their
dephosphorylation (49). The protein scaffold of PTP-IA2
could be compatible with protein binding since two point mutations in
IA2 (Ala877Asp and Asp911Ala), which in PTP1B is equivalent to the
restoration of the general acid Asp181 in the WPD loop and the
canonical Ala217 in the PTP loop, is sufficient to reconstitute
catalytic activity towards myelin basic protein phosphorylated on
tyrosine (49). Another intriguing variation of the WPD
loop is observed in four human PTP catalytic domains (PTPD1, PTPS31,
PTP
, and HDPTP) where a longer glutamate residue replaces the
general acid Asp181. This is noteworthy because (i) the WPE loop
variation is the hallmark of domain D2 sequences, which usually account
for less than 0.1% of the total activity of the full-length enzyme
(24, 38, 68, 78, 90), and (ii) this replacement in PTP1B
leads to a reduction of up to 3 orders of magnitude in catalytic
efficiency (20, 90). It will be interesting to see whether
these four PTPs have diminished enzyme activity compared to enzymes
containing a general acid aspartate residue. However, reconstitution of
the WPD motif in domain D2 of RPTP
is not sufficient to increase its
catalytic activity to a level comparable to that of domain D1,
indicating that there are structural differences other than the general
acid-base among PTP domain D1 and D2 (90) (see below).
Catalytic-water motif or Q loop (motif 10).
In the
QTXXQYXF motif (M10), two glutamine residues (Gln262 and Gln266)
and two conserved arginine residues (Arg254 and Arg257) N terminal to
this motif form crucial hydrogen bonds with interacting residues of the
PTP loop and its amide backbone. In particular, Gln262 positions and
activates an active site water molecule involved in the second
hydrolysis step of the phosphocysteine enzyme complex (61,
100). Enzyme kinetic analysis of the Yersinia PTP
combined with site-directed mutagenesis have revealed that Gln446
(equivalent to Gln262 in PTP1B) and, to a lesser extent, Gln450
(equivalent to Gln266 in PTP1B) is responsible for restricting
phosphoryl transfer from the phosphoenzyme intermediate to water and
not to other nucleophile acceptors (i.e., preventing the phosphoenzyme intermediate from acting as a kinase phosphorylating undesirable substrates [100]). Notably, within this highly variable
area of the PTP structure (Fig. 5), only these arginine and glutamine residues are invariant, consistent with their involvement in catalysis (74, 100) and critical hydrogen bonding with residues of
the PTP loop (80).
Conservation of surface-exposed amino acids in vicinity of active
site: comparison between cytoplasmic PTPs and RPTP domains D1 and
D2.
In an attempt to reveal novel structure-function
relationships, we performed the C
-regiovariation score analysis on
three subsets of PTP domains: (i) nontransmembrane PTPs, (ii)
receptor-like D1, and (iii) receptor-like D2 (Fig. 7A, B, and
C). The crystal structure of
PTP1B was used as a template for the intracellular PTPs, whereas the molecular surface conservation among the aligned RPTP
domain D1 and D2 sequences was illustrated using the X-ray crystal
structure of PTP
domain D1 (50). The interchangeable use of the PTP catalytic domains of PTP1B and PTP
for the
calculation of the C
-regiovariation score values is justified by the
excellent overlay of their tertiary structure, with a root mean
square (RMS) deviation of 1.35 Å between the two domains (the
RMS deviations between other PTP domain tertiary structures are given
in the legend to Fig. 4). Although conserved residues converged around the active site for the intracellular PTPs and for domain D1 of RPTPs
(Fig. 7A and B, respectively), the domain D2 sequences exhibited a much
greater variation in the vicinity of the active site (Fig. 7C).

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 7.
PTP domains from cytoplasmic PTPs and RPTP domains D1
and D2 show significant differences in their conservation of
surface-exposed amino acids. Shown is surface conservation (blue, most
conserved; red, least conserved) of PTP domains from nontransmembrane
PTPs (A), RPTP domains D1 (B), and RPTP domains D2 (C). Shown is the
front view looking into the active site. C -regiovariation score
values for the cytoplasmic PTPs are illustrated using the X-ray crystal
structure of PTP1B with the catalytically essential Cys215 (yel low) and epidermal growth factor receptor-derived peptide
(green) bound within the active site (closed conformation). For ease of
comparison, C -regiovariation score values among RPTP domains D1 and
D2 sequences are illustrated using the X-ray crystal structure of
RPTP domain D1 (50). The EGFR peptide (green) is
modeled in the active site of RPTP for orientation using only a
closed conformation of the X-ray crystal structures. Amino acids are
labeled according to the residue position in human PTP1B with the
equivalent residues in RPTP given in brackets (A and B). The
conserved four-residue structural linker located at the N terminus of
domain D2 (encircled area 1 in panel C), and which constrains the
relative orientation of tandem PTP domains in LAR, is compared to the
corresponding nonconserved area for the RPTP domain D1 sequences
(encircled area 1 in panel B). The amino acid residues defining this
conserved linker are boxed and colored yellow in the alignment in Fig.
1.
|
|
Our analysis of domain D2 sequences revealed several intriguing aspects
of tandem domain RPTPs. Thus, the domains D2 align extremely well with
the catalytically active PTP sequences (with CD45 accommodating an
acidic insert of 20 amino acids; Fig. 1), yet all the domains D2 are
phylogenetically distinct from domains D1 (i.e., D2 sequences do not
cluster together with D1 sequences in the phylogenetic tree but define
a separate subfamily of PTP domains (data available at
http://science.novonordisk.com/ptp). In fact, the sequence similarity
between domains D2 of LAR, RPTP
, and RPTP
(subtype R2B) is even
higher than that between the corresponding domain D1 sequences
(45). Since phylogenetic analyses have shown that PTP
domain duplication (occurring in five out of nine RPTP subfamilies)
happened very early in evolution (59) it can be argued
that there must be a separate function of the membrane distal domain in
order for these amino acids to be conserved at the present level.
Noticeably, both regulatory (38) and substrate-binding (78) functions have been proposed for these domains.
Most of the invariant amino acids in domain D1, which show considerable
substitution in domains D2, converge around the active site. Therefore,
it is noteworthy that only two point mutations (which restore the
equivalent of Tyr46 within the NXXKNRY motif) and the
general acid equivalent of Asp181 (within the WPD loop) are sufficient
to confer a robust PTP activity back to domain D2 of some RPTPs,
including PTPs (48), PTP
(9, 47), and LAR
(56). However, domains D2 of other RPTPs, such as CD45, PTP
, and RPTP
, have additional critical substitutions in several amino acids in the PTP signature motif and, therefore, are most likely
to be truly inactive (48) (Fig. 1). Nevertheless, the structural architecture of the active site signature motif of domains
D2 may still be sufficiently preserved to retain the capacity to bind
phosphotyrosine-containing proteins. Thus, the function of domain D2,
at least for some PTPs, may be similar to that of other
tyrosine-phosphate recognition units, such as SH2 domains (62) and phoshotyrosine binding domains (21).
In this regard, the C
-regiovariation score analysis of the domain D2
sequences (Fig. 7C), with the highly variable molecular surface area
surrounding the phosphate-binding site, would signify the preference
for divergent and probably highly selective protein binding partners.
Such a potential is illustrated by domain D2 of CD45, which has been shown to be critical for interleukin-2 secretion and substrate recruitment of TCR-
(41).
Identification of conserved interface between domains D1 and D2 of
RPTPs.
When comparing the RPTP domains D1 and D2 sequences by
using the X-ray crystal structure of RPTP
domain D1 as template
(79), the encircled area 1 in Fig. 7 was found to be
highly conserved among RPTP domain D2 sequences (Fig. 7C) but not among
RPTP domain D1 sequences (Fig. 7B). Significantly, the residues in this
area (Fig. 1, boxed in yellow) were recently identified as the
structural linker that constrains the relative orientation of the two
PTP domains in LAR (56). Although this is so far the only
report describing the X-ray crystal structure of the tandem arrangement of PTP domains, our alignment reveals that this structural linker is
highly conserved among all tandem domain-containing RPTPs, suggesting
conservation in function. The consensus motif for this four-residue
linker is G[D/E]TE (Fig. 1, highlighted in yellow).
In addition to the structural linker, our C
-regiovariation score
analysis of RPTP domains D1 and D2 identified additional conserved
residues (Fig. 8B and C, encircled area
II), which were confined to the region of the PTP tertiary structure
that correlates with the interdomain interface revealed by the X-ray
crystal structure of LAR (56). Again, the
C
-regiovariation score analysis predicted the exact location of the
interface in domain D2, including hydrogen bonding polar residues and
conserved hydrophobic residues responsible for the extensive van der
Waals interactions and tight complementary fit described for the
interface between domains D1 and D2 of LAR (56). For the
PTP domains in Fig. 8B, the center of conservation is less focused on
the exact residues involved in this interface, but when the
single-domain RPTPs (subtypes R3, R7, and R8) were removed from the
C
-regiovariation score analysis, the conservation of this area in
domain D1 became even more apparent (not shown). Significantly, the
lack of conservation of this region for the nontransmembrane PTPs (Fig.
8A) illustrates that this interface is unique to tandem domain RPTPs
(Fig. 8B and C).

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 8.
Identification of novel conserved area on surface of PTP
domain opposite active site. Shown are surface conservation
(C -regiovariation score values) among nontransmembrane PTPs (A),
RPTP domains D1 (B), and RPTP domains D2 (C). The tertiary structure is
rotated 180° compared to structures in Fig. 7, showing the surface of
the molecule opposite the active site. Encircled area II (B and C)
corresponds to the interface for domains D1 and D2 as revealed in the
X-ray crystal structure of LAR (56). Encircled area III is
a novel putative interactive site, which appears to be conserved in all
three subsets of PTP domain sequences. Amino acids are labeled
according to the residue positions in PTP1B (A) and RPTP (B
and C).
|
|
Identification of novel conserved pocket on surface of PTP domain
opposite active site.
In addition to the identification of
conserved regions surrounding the active site and at the interface
between domains D1 and D2 of RPTPs, the C
-regiovariation score
analysis identified another focus of conservation that was confined to
the area of the molecule opposite the active site (Fig. 8A, B, and C,
encircled area III). This surface-accessible area of conservation
extends above a shallow hydrophobic pocket formed by residues IIe57,
Ala69, IIe82, and Met98. These four residues have adopted a
configuration that accommodates extensive van der Waals interactions
and only one PTP (the Xenopus, mouse, and human
orthologs of MEG2) has accepted nonconservative changes to
residues within this pocket. In addition, residues from motif 2 (DXXRVXL) and motif 5 (TXXDFWXMXW) contribute
to this conserved microenvironment, which explains why this cluster of
conservation can be identified only when the PTP chain fold is considered.
Size and physiochemical nature of conserved pocket is consistent
with recognition site for protein-protein interaction.
Statistical
examination of protein-protein associations suggests a central role for
hydrophobic residues at interfacial regions (40, 67). In
terms of amino acid composition at protein-protein domain interfaces,
it has been noted that there is a preference for larger, nonpolar
residues, particularly aromatic amino acids, as well as a few key basic
or acidic residues (87). Indeed, from the alignment
analysis, we observed that the conserved residues residing on the rim
and within the shallow pocket (Fig. 8, encircled area III) are more
hydrophobic and aromatic than the remainder of the surface of the PTP
molecule, with several charged residues surrounding the hydrophobic
pocket. Therefore, the amino acid composition in this region of the PTP
molecule is consistent with the identification of a possible novel site
of interaction. The size of the solvent-accessible area that appears
conserved (i.e., the dark blue area) is ~250
Å2. Usually, the area of protein-protein
interaction surfaces are larger (~700 Å2), typically
constituting from 7 to 30% of the total surface area of a monomer
(39, 87). However, extensive additional surface area can
be included in this putative interaction site of the PTP domain if the
adjacent less-conserved residues (i.e., the white area in Fig. 8) are
considered in the evaluation.
In conclusion, the regiovariation score analysis has led to the
identification of the catalytic active site, the conserved linker
between domains D1 and D2 as revealed by the X-ray crystal structure of
LAR, as well as the approximate surface area of interaction between
domain D1 and D2. In addition, our analysis highlights a focus of
conservation on the surface of the PTP domain opposite the active site.
Although the conservation of this pocket may be of structural
importance, it is tempting to speculate the existence of additional
roles for this site in effector interactions with other protein domains
or signaling molecules. However, mutational and functional studies of
appropriate PTP mutants will be necessary to corroborate the
significance of residues in this area of the PTP domain.
Identification of nonconserved residues surrounding active
site
implications for substrate recognition and inhibitor design.
In addition to the identification of three-dimensionally conserved
regions, the C
-regiovariation score analysis offers a unique
opportunity to identify areas in a protein family that are less well
conserved and therefore might indicate a specialized function. As an
example, analysis of areas in the proximity of the active site of
enzymes, here PTPs, may lead to the identification of putative
substrate-binding pockets. Furthermore, such analysis in conjunction
with primary sequence alignments may allow the identification of unique
combinations of amino acid residues that can be addressed in a
structure-based design of selective inhibitors.
At present, two PTPs have been cocrystallized with peptide substrates,
PTP1B (37, 74, 75) and SHP1 (91). Although significant differences in the binding modes were observed (see below),
both studies show peptide binding to residues defined by the
1/
1
loop and the M10 motif (
5-loop-
6) (Fig. 1). Some of these
residues, such as Tyr46 and Gln262, are highly conserved and hence
likely to be involved in the binding or catalysis of all
phosphotyrosine substrates. However, other residues are quite variable
and are potentially responsible for defining substrate selectivity.
Significantly, our structural alignment analysis identifies at least
four areas in proximity to the active site which are nonconserved and
for which involvement in the recognition of peptides and small molecule
ligands have been documented in biochemical and crystallographic
studies (Fig. 9). Although no single
residue in these areas appears to be a unique hallmark of any
particular PTP, the combination of residues in these areas is unique
and could consequently represent a selectivity-determining region. This
is probably most apparent for the region defined by residues 47, 48, 258, and 259 of PTP1B (Fig. 9). In agreement with this, we have
recently shown that residue 259 is a key determinant in substrate
recognition and catalysis (66). Thus, the residue at
position 259 in PTP1B is a glycine, which forms the bottom of an open
cleft that creates access to a second binding pocket adjacent to the
active site. This structural feature in PTP1B, together with the
plasticity conferred by Arg47 in accommodating either acidic residues
at the P-1 and P-2 positions in the substrate (as illustrated in the
EGFR988-993 peptide) (37) or hydrophobic residues at P-1
(75), explains why PTP1B is able to accommodate a broad
range of artificial peptide substrates in vitro. In contrast, PTPs with
bulky residues at the position equivalent to 259 in PTP1B including
RPTP
and LAR show more limited peptide recognition capacity in
vitro. We have shown recently by kinetic and X-ray crystallographic
studies that replacing the bulky Gln259 residue in PTP
with a
glycine converts PTP
into a PTP1B-like enzyme and vice versa
(66). However, in a physiological context, the presence of
a glycine at position 259 in PTP1B allows for high-affinity binding of
substrates, such as the activation loop of the insulin receptor, which
contain two adjacent phosphotyrosine residues (74). Thus,
the simultaneous engagement of the substrate phosphotyrosine residue in
the active site and the adjacent phosphotyrosine residue at a second
substrate-binding pocket may make an important contribution to the
substrate recognition by PTP1B in vivo.

View larger version (95K):
[in this window]
[in a new window]
|
FIG. 9.
Nonconserved amino acids in the proximity of the PTP
active site are involved in the recognition of PTP substrates and
nonpeptide PTP inhibitors. Shown is the visualization of four
selectivity-determining regions on the molecular surface of PTP1B.
Areas of conservation (blue, most conserved; red, least conserved)
represent the C -regiovariation score values of 37 aligned human PTP
catalytic domains (values from Fig. 5). The amino acids involved in
defining these four selectivity-determining regions are indicated
(boxed) in the alignment in Fig. 1.
|
|
The most important residues in this second phosphotyrosine binding site
of PTP1B appear to be Arg24 and Arg254. Although Arg254 is a highly
conserved residue, the presence of Arg24 and Gly259 seems to be unique
to PTP1B and TC-PTP. The tethering together of a ligand that
simultaneously occupies the active site with a ligand that interacts
with residues of this second phosphotyrosine binding pocket has been
suggested as a paradigm for PTP1B inhibitor design (69)
resulting in remarkably selective bis(aryldifluorophosphonate) inhibitors of PTP1B (81). Furthermore, and consistent with
this paradigm, Ramachadran and colleagues have recently reported that peptides containing two nonhydrolyzable analogs of phosphotyrosine [difluoro(phospho)methyl-phenylalanine] were potent and specific inhibitors of PTP1B, illustrating that exquisite substrate and inhibitor selectivity exists in close vicinity to the active sites of
PTPs (15).
In addition, other areas in the proximity of the active site show
considerable variability and could potentially be involved in defining
substrate specificity (Fig. 9). One such area is defined by
5-loop-
6 (i.e., between the M6 and M7 motifs). Whereas no substrate binding has been observed in this region in PTP1B, a study of
SHP1 that had cocrystallized with two different synthetic peptides
revealed significant interaction within this region, in one case due to
salt bridge formation between AspP-4 in the peptide
substrate and Arg360 in SHP-1 (corresponding to S118 in PTP1B)
(91). Interestingly, this region is quite different in
SHP2. Therefore, these X-ray crystallographic studies provide structural support for the observed different substrate specificities of these closely related SH2 domain-containing PTPs, as demonstrated in
two elegant catalytic-domain-swapping experiments (60,
82). Although no direct interaction has been observed in the
crystal structure of PTP1B complexed with peptide substrates,
computational studies suggest a similar role of this region in
substrate recognition by PTP1B (64). However, for the SHP1
cocrystal, it should be noted that binding of peptide substrate to the
PTP catalytic domain did not bring the WPD loop into its closed
conformation (91), thus raising the question of whether it
is a catalytically competent complex.
Since such unique aspects of the structure in the vicinity of the
active site contribute to substrate specificity, we investigated whether selective nonphosphonate, nonpeptide inhibitors of PTP1B could
be obtained by addressing one of these regions. Our attention was
directed to Asp48 and Arg47 in PTP1B. As a starting point, we used a
general PTP inhibitor, 2-(oxalylamino)-benzoic acid, which we had
identified by high-throughput screening of the Novo Nordisk compound
library. We reasoned that a correctly positioned basic nitrogen in the
inhibitor would be able to form a salt bridge with the side chain of
Asp48 in PTP1B, whereas an asparagine, which is found in the equivalent
position in many other PTPs, would cause repulsion (Fig. 1). Indeed, a
low-molecular-weight, nonphosphorus compound containing such a basic
nitrogen displayed a remarkable selectivity for PTP1B
(36). Recently, studies with PTP1B knockout mice
(17, 44) and PTP1B antisense oligonucleotides have
provided compelling evidence that inhibition of PTP1B may be an
effective approach for the treatment of diabetes and obesity (53). The identification of selectivity-determining
regions suggests that it may be possible to generate specific
inhibitors of PTP1B for use in this context. Furthermore, it is now
becoming apparent that the inhibition of other members of the PTP
family may offer novel strategies for therapeutic interaction in
various human diseases. We hope that the analysis presented here will not only assist in further characterization of the PTP family but also
may contribute to the development of selective inhibitors of other
potential drug targets within the PTP family.
This work was supported by an industrial Ph.D. fellowship from
the Danish Academy of Technical Sciences (J.N.A) and grants from the
NIH (RO1 CA53840 and GM 55989) and the Mellam Family Foundation
(N.K.T).
| 1.
|
Alexander, D. R.
2000.
The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell function.
Semin. Immunol.
12:349-359[CrossRef][Medline].
|
| 2.
|
Altschul, S. F.,
W. Gish,
W. Miller,
E. W. Myers, and D. J. Lipman.
1990.
Basic local alignment search tool.
J. Mol. Biol.
215:403-410[CrossRef][Medline].
|
| 3.
|
Andersen, J. N.,
A. Elson,
R. Lammers,
J. Romer,
J. Clausen,
K. B. Moller, and N. P. H. Moller.
2001.
Comparative study of protein tyrosine phosphatase epsilon isoforms: membrane localization confers specificity in cellular signalling.
Biochem. J.
354:581-590[CrossRef][Medline].
|
| 4.
|
Angers-Loustau, A.,
J. F. Cote, and M. L. Tremblay.
1999.
Roles of protein tyrosine phosphatases in cell migration and adhesion.
Biochem. Cell. Biol.
77:493-505[CrossRef][Medline].
|
| 5.
|
Apweiler, R.,
T. K. Attwood,
A. Bairoch,
A. Bateman,
E. Birney,
M. Biswas,
P. Bucher,
L. Cerutti,
F. Corpet,
M. D. Croning,
R. Durbin,
L. Falquet,
W. Fleischmann,
J. Gouzy,
H. Hermjakob,
N. Hulo,
I. Jonassen,
D. Kahn,
A. Kanapin,
Y. Karavidopoulou,
R. Lopez,
B. Marx,
N. J. Mulder,
T. M. Oinn,
M. Pagni, and F. Servant.
2001.
The InterPro database, an integrated documentation resource for protein families, domains and functional sites.
Nucleic Acids Res.
29:37-40[Abstract/Free Full Text].
|
| 6.
|
Barford, D.,
A. K. Das, and M. P. Egloff.
1998.
The structure and mechanism of protein phosphatases insights into catalysis and regulation.
Annu. Rev. Biophys. Biomol. Struct.
27:133-164[CrossRef][Medline].
|
| 7.
|
Barford, D.,
A. J. Flint, and N. K. Tonks.
1994.
Crystal-structure of human protein-tyrosine-phosphatase 1B.
Science
263:1397-1404[Abstract/Free Full Text].
|
| 8.
|
Brady-Kalnay, S. M., and N. K. Tonks.
1995.
Protein-tyrosine phosphatases as adhesion receptors.
Curr. Opin. Cell Biol.
7:650-657[CrossRef][Medline].
|
| 9.
|
Buist, P.,
Y. L. Zhang,
Y. F. Keng,
L. Wu,
Z. Y. Zhang, and J. den Hertog.
1999.
Restoration of potent protein-tyrosine phosphatase activity into the membrane-distal domain of receptor protein-tyrosine phosphatase alpha.
Biochemistry
38:914-922[CrossRef][Medline].
|
| 10.
|
Cardle, L., and M. J. Dufton.
1994.
Identification of important functional environs in protein tertiary structures from the analysis of residue variation in 3D application to cytochromes-c and carboxypeptidase-a and carboxypeptidase-b.
Protein Eng.
7:1423-1431[Abstract/Free Full Text].
|
| 11.
|
Cardle, L., and M. J. Dufton.
1997.
Foci of amino-acid residue conservation in the 3D structures of proteinase-inhibitors how do variants from snake-venom differ.
Protein Eng.
10:131-136[Abstract/Free Full Text].
|
| 12.
|
Cho, H.,
S. E. Ramer,
M. Itoh,
E. Kitas,
W. Bannwarth,
P. Burn,
K. Saito, and C. T. Walsh.
1992.
Catalytic domains of LAR and CD45 protein tyrosine phosphatases from Escherichia coli expression systems: purification and characterization for specificity and mechanism.
Biochemistry
31:133-138[CrossRef][Medline].
|
| 13.
|
Denu, J. M.,
D. L. Lohse,
J. Vijayalakshmi,
M. A. Saper, and J. E. Dixon.
1996.
Visualization of intermediate and transition-state structures in protein-tyrosine-phosphatase catalysis.
Proc. Natl. Acad. Sci. USA
93:2493-2498[Abstract/Free Full Text].
|
| 14.
|
Denu, J. M., and K. G. Tanner.
1998.
Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation.
Biochemistry
37:5633-5642[CrossRef][Medline].
|
| 15.
|
Desmarais, S.,
R. W. Friesen,
R. Zamboni, and C. Ramachandran.
1999.
[Difluro(phosphono)methyl]phenylalanine-containing peptide inhibitors of protein tyrosine phosphatases.
Biochem. J.
337:219-223.
|
| 16.
|
Dill, K. A.
1999.
Polymer principles and protein folding.
Protein Sci.
8:1166-1180[Abstract].
|
| 17.
|
Elchebly, M.,
P. Payette,
E. Michaliszyn,
W. Cromlish,
S. Collins,
A. L. Loy,
D. Normandin,
A. Cheng,
J. Himms-Hagen,
C. C. Chan,
C. Ramachandran,
M. J. Gresser,
M. L. Tremblay, and B. P. Kennedy.
1999.
Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene.
Science
283:1544-1548[Abstract/Free Full Text].
|
| 18.
|
Elson, A., and P. Leder.
1995.
Identification of a cytoplasmic, phorbol ester-inducible isoform of protein-tyrosine-phosphatase epsilon.
Proc. Natl. Acad. Sci. USA
92:12235-12239[Abstract/Free Full Text].
|
| 19.
|
Fischer, E. H.
1999.
Cell signaling by protein tyrosine phosphorylation.
Adv. Enzyme Regul.
39:359-369[CrossRef][Medline].
|
| 20.
|
Flint, A. J.,
T. Tiganis,
D. Barford, and N. K. Tonks.
1997.
Development of substrate-trapping mutants to identify physiological substrates of protein-tyrosine phosphatases.
Proc. Natl. Acad. Sci. USA
94:1680-1685[Abstract/Free Full Text].
|
| 21.
|
Forman-Kay, J. D., and T. Pawson.
1999.
Diversity in protein recognition by PTB domains.
Curr. Opin. Struct. Biol.
9:690-695[Medline].
|
| 22.
|
Frisch, S. M.,
K. Vuori,
E. Ruoslahti, and P. Y. Chanhui.
1996.
Control of adhesion-dependent cell-survival by focal adhesion kinase.
J. Cell. Biol.
134:793-799[Abstract/Free Full Text].
|
| 23.
|
Garton, A.,
A. J. Flint, and N. K. Tonks.
1996.
Identification of p130(cas) as a substrate for the cytosolic protein tyrosine phosphatase PTP-PEST.
Mol. Cell. Biol.
16:6408-6418[Abstract].
|
| 24.
|
Gebbink, M. F. B. G.,
M. H. G. Verheijen,
G. C. M. Zondag,
I. Vanetten, and W. H. Moolenaar.
1993.
Purification and characterization of the cytoplasmic domain of human receptor-like protein-tyrosine-phosphatase RPTPµ.
Biochemistry
32:13516-13522[CrossRef][Medline].
|
| 25.
|
Guan, K. L., and J. E. Dixon.
1991.
Evidence for protein-tyrosine-phosphatase catalysis proceeding via a cysteine-phosphate intermediate.
J. Biol. Chem.
266:17026-17030[Abstract/Free Full Text].
|
| 26.
|
Hanks, S. K., and A. M. Quinn.
1991.
Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members.
Methods Enzymol.
200:38-62[Medline].
|
| 27.
|
Hof, P.,
S. Pluskey,
S. Dhepaganon,
M. J. Eck, and S. E. Shoelson.
1998.
Crystal-structure of the tyrosine phosphatase shp-2.
Cell
92:441-450[CrossRef][Medline].
|
| 28.
|
Hoff, R. H.,
A. C. Hengge,
L. Wu,
Y. F. Keng, and Z. Y. Zhang.
2000.
Effects on general acid catalysis from mutations of the invariant tryptophan and arginine residues in the protein tyrosine phosphatase from Yersinia.
Biochemistry
39:46-54[CrossRef][Medline].
|
| 29.
|
Hoffmann, K. M. V.,
N. K. Tonks, and D. Barford.
1997.
The crystal-structure of domain-1 of receptor protein-tyrosine-phosphatase-µ.
J. Biol. Chem.
272:27505-27508[Abstract/Free Full Text].
|
| 30.
|
Hubbard, S. R., and J. H. Till.
2000.
Protein tyrosine kinase structure and function Annu.
Rev. Biochem.
69:373-398[CrossRef][Medline].
|
| 31.
|
Hunter, T.
2000.
Signaling 2000 and beyond.
Cell
100:113-127[CrossRef][Medline].
|
| 32.
|
Hunter, T.
1995.
Protein-kinases and phosphatases the yin and yang of protein-phosphorylation and signaling.
Cell
80:225-236[CrossRef][Medline].
|
| 33.
|
Hunter, T.
1998.
The Onian-lecture 1997 the phosphorylation of proteins on tyrosine its role in cell-growth and disease.
Philos. Trans. R. Soc. Lond. Biol. Sci.
353:583-605[CrossRef][Medline].
|
| 34.
|
Huyer, G.,
S. Liu,
J. Kelly,
J. Moffat,
P. Payette,
B. Kennedy,
G. Tsaprailis,
M. J. Gresser, and C. Ramachandran.
1997.
Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate.
J. Biol. Chem.
272:843-851[Abstract/Free Full Text].
|
| 35.
|
Ibarra-Sanchez, M.,
P. D. Simoncic,
F. R. Nestel,
P. Duplay,
W. S. Lapp, and M. L. Tremblay.
2000.
The T-cell protein tyrosine phosphatase.
Semin. Immunol.
12:379-386[CrossRef][Medline].
|
| 36.
|
Iversen, L. F.,
H. S. Andersen,
S. Branner,
S. B. Mortensen,
G. H. Peters,
K. Norris,
O. H. Olsen,
C. B. Jeppesen,
B. F. Lundt,
W. Ripka,
K. B. Moller, and N. P. H. Moller.
2000.
Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B.
J. Biol. Chem.
275:10300-10307 |